536 related articles for article (PubMed ID: 32572523)
1. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
6. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
[TBL] [Abstract][Full Text] [Related]
7. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies.
Li HH; Li F; Gao CJ; Huang WR; Bo J; Dou LP; Wang LL; Jing Y; Wang L; Li WJ; Yu L; Liu DH
Br J Haematol; 2017 Jan; 176(1):92-100. PubMed ID: 27714774
[TBL] [Abstract][Full Text] [Related]
8. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q
Front Immunol; 2022; 13():1036403. PubMed ID: 36389692
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus.
Chen Y; Xu LP; Liu KY; Chen H; Chen YH; Zhang XH; Wang Y; Wang FR; Han W; Wang JZ; Yan CH; Huang XJ
J Clin Virol; 2016 Feb; 75():10-5. PubMed ID: 26735213
[TBL] [Abstract][Full Text] [Related]
11. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
[TBL] [Abstract][Full Text] [Related]
12. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
14. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
Dou L; Hou C; Ma C; Li F; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
Ann Hematol; 2020 Jan; 99(1):167-179. PubMed ID: 31828376
[TBL] [Abstract][Full Text] [Related]
15. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis.
Ando T; Suzuki T; Ishiyama Y; Koyama S; Tachibana T; Tanaka M; Kanamori H; Nakajima H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):171-177. PubMed ID: 31563574
[TBL] [Abstract][Full Text] [Related]
16. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies.
Huang W; Li H; Gao C; Bo J; Wang Q; Zhao Y; Jing Y; Wang S; Zhu H; Dou L; Wang L; Yu L
Transfusion; 2012 Jun; 52(6):1354-62. PubMed ID: 22233440
[TBL] [Abstract][Full Text] [Related]
17. Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial.
Wang H; Wang N; Wang L; Du J; Li F; Shao Y; Peng B; Luan S; Wang L; Jin X; Gao C; Dou L; Liu D
Am J Hematol; 2023 Nov; 98(11):1732-1741. PubMed ID: 37706580
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings.
Ma YR; Xu LP; Zhang XH; Liu KY; Chang YJ; Lv M; Yan CH; Chen YH; Han W; Wang FR; Mo XD; Huang XJ; Wang Y
Ann Hematol; 2021 Feb; 100(2):555-562. PubMed ID: 33415424
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study.
Zheng FM; Zhang X; Li CF; Cheng YF; Gao L; He YL; Wang Y; Huang XJ
Cancer Commun (Lond); 2020 Mar; 40(2-3):93-104. PubMed ID: 32175698
[TBL] [Abstract][Full Text] [Related]
20. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
